A randomized controlled trial investigated Mika, our app-based digital therapeutic company, in reducing distress among cancer patients.
This randomized controlled trial in Germany enrolled patients with cancer across all tumour entities diagnosed within the last 5 years. Participants were randomized into the intervention (Mika plus usual care) and control (usual care alone) groups. The participants completed web-based assessments at baseline and at 2, 6, and 12 weeks. The primary outcome was the change in distress from baseline to week 12, as measured by the National Comprehensive Cancer Network Distress Thermometer. Secondary outcomes included depression, anxiety, fatigue, and quality of life. Intention-to-treat and per-protocol analyses were performed.
Results showed that Mika effectively diminished distress in patients with cancer. As a digital therapeutic solution, Mika offers accessible, tailored psychosocial and self-management support to address the unmet needs in cancer care.
Discover more here.